

# 2016-2020 Strategy: Progress Challenges and Risks

---


BOARD MEETING

**Anuradha Gupta**

28-29 November 2018, Geneva, Switzerland







# Alliance on track to achieve its 2020 mission indicators





**SG1: Accelerate vaccines**


# Mixed performance: challenges and risks remain






# Diphtheria outbreaks: reminder of gaps in routine immunisation


## Haiti



## Yemen



## Bangladesh Cox's Bazar district






Diphtheria

**601 cases**

**2,081 cases**

**7,062 cases**


DTP3  
Coverage  
2017






**SG2: Strengthen systems**

# Strengthening routine immunisation delivery: Strategic shifts but more work to be done



# DRC: Using all Gavi levers to improve coverage and equity

## Subnational focus in 9 provinces



### Political will

Sustained Alliance engagement



### LMC

"Mashako plan" in 9 provinces



### Supply Chain

Cold chain equipment to expand from 16% to 80% health facilities



### Data

DHIS2 rollout and HMIS strengthening

UiO : University of Oslo



### Innovations

Exploration of vaccine delivery by drones



### CSOs

social mobilization in 20,000 villages



### Collaboration with Global Fund, WB and GFF


on performance based financing






# Emerging risks in high coverage countries

Recent drop in coverage in Kyrgyzstan (Penta3)



Subnational level coverage Penta3



# PENCANANGAN KAMPANYE IMUNISASI MEASLES RUBELLA (MR) OLEH PRESIDEN REPUBLIK INDONESIA


Sleman, 1 Agustus 2017

**SG3: Improve sustainability**




# Gavi leading the way on sustainability


## CO-FINANCING & SELF-FINANCING




## COUNTRIES INVESTMENT IN VACCINES



## CO-FINANCING COMMITMENTS



## COUNTRIES ON TRACK TO TRANSITION







## SG4: Market shaping

Ringers Lactate, 500ml B.P.  
No. of units / carton: 25 bottles  
PO no.: 45003234-2





Ringers Lactate, 300ml B.P.  
No. of units / carton: 25 bottles  
PO no.: 45003234-2

Ringers Lactate, 300ml B.P.  
No. of units / carton: 25 bottles  
PO no.: 45003234-2


Ringers Lactate, 300ml B.P.  
No. of units / carton: 25 bottles  
PO no.: 45003234-2



# Successful market shaping for vaccines; new risks are emerging



# Key risks are evolving and being monitored



● Programmatic risk

● Corporate risk

▲ Recent evolution

### Very high risks

- a) Country management capacity
- b) Data quality ▼
- c) Ability to reach the under-immunised ▼
- d) Sustainable transition

### High risks

- e) Insufficient demand
- f) Outbreaks disrupt immunisation
- g) Misuse by countries
- h) Donor support
- i) Polio transition NEW
- j) IT disruption NEW
- k) Strategic relevance
- l) Frequent or unplanned campaigns ▲
- m) Partner capacity ▼
- n) Global supply shortages
- o) HSIS value for money
- p) Forecasting variability
- q) Secretariat disruption ▼



**THANK YOU**